{"id":59230,"date":"2026-03-11T13:14:25","date_gmt":"2026-03-11T05:14:25","guid":{"rendered":"https:\/\/flcube.com\/?p=59230"},"modified":"2026-03-11T13:14:26","modified_gmt":"2026-03-11T05:14:26","slug":"keymed-biosciences-initiates-cmg901-phase-iii-astrazeneca-triggers-45-million-milestone-for-claudin-18-2-adc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59230","title":{"rendered":"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC"},"content":{"rendered":"\n<p><strong>Keymed Biosciences Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2162:HKG\">HKG: 2162<\/a>) announced the <strong>initiation of Phase III clinical trials<\/strong> for <strong>CMG901<\/strong>, its <strong>Claudin 18.2-targeted antibody-drug conjugate (ADC)<\/strong>, triggering a <strong>$45\u202fmillion milestone payment<\/strong> from <strong>AstraZeneca<\/strong>. The payment, received net of bank charges, represents progress under the <strong>2023 global exclusive license agreement<\/strong> between <strong>KYM Biosciences<\/strong> (Keymed&#8217;s 70%-owned JV) and AstraZeneca, which included <strong>$63\u202fmillion upfront<\/strong> and <strong>>$1.1\u202fbillion in potential milestones<\/strong>. The Phase III launch validates CMG901&#8217;s <strong>first-in-class potential<\/strong> in <strong>gastric and gastroesophageal junction (GEJ) cancer<\/strong>, where Claudin 18.2 expression drives significant unmet need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-amp-milestone-overview\">Transaction &amp; Milestone Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>CMG901 (Claudin 18.2-targeted ADC)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Keymed Biosciences (HKG: 2162) via KYM Biosciences JV (70% stake)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>AstraZeneca (global exclusive licensee)<\/td><\/tr><tr><td><strong>Agreement Date<\/strong><\/td><td>February 2023<\/td><\/tr><tr><td><strong>Deal Structure<\/strong><\/td><td>$63\u202fmillion upfront + &gt;$1.1\u202fbillion milestones + royalties<\/td><\/tr><tr><td><strong>Milestone Triggered<\/strong><\/td><td>Phase III initiation<\/td><\/tr><tr><td><strong>Milestone Amount<\/strong><\/td><td>$45\u202fmillion (received net of bank charges)<\/td><\/tr><tr><td><strong>Phase III Start<\/strong><\/td><td>March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>CMG901 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>Claudin 18.2 (tight junction protein overexpressed in gastric\/GEJ cancer)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Components<\/strong><\/td><td>Anti-Claudin 18.2 monoclonal antibody + cleavable linker + cytotoxic payload<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Targeted delivery of cytotoxic agent to Claudin 18.2-positive tumor cells; bystander killing of neighboring cells<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Optimized binding affinity for Claudin 18.2 isoform (excludes 18.1 to reduce off-tumor toxicity)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Clinical Development Trajectory:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase I\/II:<\/strong> Demonstrated promising efficacy and manageable safety in gastric\/GEJ cancer<\/li>\n\n\n\n<li><strong>Phase III:<\/strong> Global registrational study vs. standard of care (chemotherapy \u00b1 nivolumab)<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Simultaneous China and Western market filings anticipated<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Gastric Cancer Burden<\/strong><\/td><td>China: 480,000+ annual cases; 5-year survival &lt;30% in advanced disease; Claudin 18.2 expressed in ~40% of patients<\/td><\/tr><tr><td><strong>Claudin 18.2 Competition<\/strong><\/td><td>Zolbetuximab (Astellas) approved 2024 (mAb); CMG901 ADC mechanism offers superior potency and bystander effect<\/td><\/tr><tr><td><strong>AstraZeneca Oncology<\/strong><\/td><td>CMG901 complements AZ&#8217;s gastric cancer portfolio (Enhertu, Imfinzi); leverages global commercial infrastructure<\/td><\/tr><tr><td><strong>Keymed Value Creation<\/strong><\/td><td>$45M milestone validates platform; Series A backer Hankang Capital continues support through subsequent rounds<\/td><\/tr><tr><td><strong>China Biotech Premium<\/strong><\/td><td>Keymed&#8217;s ADC platform attracts multinational partnerships; validates domestic innovation quality<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Status<\/th><th>CMG901 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Astellas<\/strong><\/td><td>Vyloy (zolbetuximab)<\/td><td>Claudin 18.2 mAb<\/td><td>Approved (1L gastric)<\/td><td>ADC payload provides cytotoxic potency vs. ADCC alone<\/td><\/tr><tr><td><strong>Amgen<\/strong><\/td><td>AMG 199<\/td><td>Claudin 18.2\/CD3 BiTE<\/td><td>Phase I<\/td><td>CMG901 established later-stage development<\/td><\/tr><tr><td><strong>Legend Biotech<\/strong><\/td><td>LB-1901<\/td><td>Claudin 18.2 CAR-T<\/td><td>Phase I<\/td><td>Off-the-shelf ADC vs. personalized cell therapy<\/td><\/tr><tr><td><strong>Keymed\/AZ<\/strong><\/td><td><strong>CMG901<\/strong><\/td><td><strong>Claudin 18.2 ADC<\/strong><\/td><td><strong>Phase III<\/strong><\/td><td><strong>First-in-class ADC; global Phase III with Big Pharma partner<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-development-outlook\">Financial &amp; Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Milestone Payments<\/strong><\/td><td>$45M Phase III trigger received; additional milestones for regulatory approvals, sales thresholds<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered double-digit on global net sales<\/td><\/tr><tr><td><strong>Keymed Ownership<\/strong><\/td><td>70% of KYM Biosciences; AstraZeneca holds commercialization rights<\/td><\/tr><tr><td><strong>Use of Funds<\/strong><\/td><td>Phase III execution; manufacturing scale-up; pipeline expansion (Claudin 18.2 diagnostics, combinations)<\/td><\/tr><tr><td><strong>Valuation Impact<\/strong><\/td><td>HKG: 2162 shares expected to react positively to milestone validation and Phase III progress<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III enrollment timelines, regulatory pathways, and milestone achievement for CMG901. Actual results may differ due to competitive dynamics with zolbetuximab, manufacturing scale-up challenges, and gastric cancer trial execution risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,130,974,179],"class_list":["post-59230","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-astrazeneca","tag-hkg-2162","tag-keymed-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45\u202fmillion milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed&#039;s 70%-owned JV) and AstraZeneca, which included $63\u202fmillion upfront and &gt;$1.1\u202fbillion in potential milestones. The Phase III launch validates CMG901&#039;s first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59230\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC\" \/>\n<meta property=\"og:description\" content=\"Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45\u202fmillion milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed&#039;s 70%-owned JV) and AstraZeneca, which included $63\u202fmillion upfront and &gt;$1.1\u202fbillion in potential milestones. The Phase III launch validates CMG901&#039;s first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59230\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T05:14:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T05:14:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59230#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59230\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC\",\"datePublished\":\"2026-03-11T05:14:25+00:00\",\"dateModified\":\"2026-03-11T05:14:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59230\"},\"wordCount\":500,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"HKG: 2162\",\"Keymed Biosciences\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59230#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59230\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59230\",\"name\":\"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-11T05:14:25+00:00\",\"dateModified\":\"2026-03-11T05:14:26+00:00\",\"description\":\"Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45\u202fmillion milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed's 70%-owned JV) and AstraZeneca, which included $63\u202fmillion upfront and >$1.1\u202fbillion in potential milestones. The Phase III launch validates CMG901's first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59230#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59230\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59230#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC - Insight, China&#039;s Pharmaceutical Industry","description":"Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45\u202fmillion milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed's 70%-owned JV) and AstraZeneca, which included $63\u202fmillion upfront and >$1.1\u202fbillion in potential milestones. The Phase III launch validates CMG901's first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59230","og_locale":"en_US","og_type":"article","og_title":"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC","og_description":"Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45\u202fmillion milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed's 70%-owned JV) and AstraZeneca, which included $63\u202fmillion upfront and >$1.1\u202fbillion in potential milestones. The Phase III launch validates CMG901's first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.","og_url":"https:\/\/flcube.com\/?p=59230","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T05:14:25+00:00","article_modified_time":"2026-03-11T05:14:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59230#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59230"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC","datePublished":"2026-03-11T05:14:25+00:00","dateModified":"2026-03-11T05:14:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59230"},"wordCount":500,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","AstraZeneca","HKG: 2162","Keymed Biosciences"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59230#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59230","url":"https:\/\/flcube.com\/?p=59230","name":"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-11T05:14:25+00:00","dateModified":"2026-03-11T05:14:26+00:00","description":"Keymed Biosciences Inc. (HKG: 2162) announced the initiation of Phase III clinical trials for CMG901, its Claudin 18.2-targeted antibody-drug conjugate (ADC), triggering a $45\u202fmillion milestone payment from AstraZeneca. The payment, received net of bank charges, represents progress under the 2023 global exclusive license agreement between KYM Biosciences (Keymed's 70%-owned JV) and AstraZeneca, which included $63\u202fmillion upfront and >$1.1\u202fbillion in potential milestones. The Phase III launch validates CMG901's first-in-class potential in gastric and gastroesophageal junction (GEJ) cancer, where Claudin 18.2 expression drives significant unmet need.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59230#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59230"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59230#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Keymed Biosciences Initiates CMG901 Phase III \u2013 AstraZeneca Triggers $45\u202fMillion Milestone for Claudin 18.2 ADC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59230"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59230\/revisions"}],"predecessor-version":[{"id":59231,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59230\/revisions\/59231"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}